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ABSTRACT
Objective: This work aims to determine the effect of iron overload on serum Anti-Müllerian hormone (AMH) levels in females with transfusion-
dependent β-thalassemia by measuring serum ferritin and to investigate the effects of iron chelation therapy including oral deferiprone (DFP) and 
subcutaneous deferoxamine (DFO) in the management of transfusion-related iron overload together with reproductive function.
Methods: A total of 90 female patients with thalassemia major (TM), thalassemia intermedia (TI) and thalassemia minor (T minor) were selected to 
investigate AMH by enzyme-linked immunosorbent assay and ferritin by immunoradiometric assay.
Results: Serum AMH level was lower in female patients with transfusion-dependent β-thalassemia than in T minor also, ferritin was 25 fold more 
in TM compared to T minor (3088.0±2497.6 ng/ml vs. 120.3±36.2 ng/ml). There was a significant negative correlation of AMH with ferritin in TM 
(r=−0.949, *p<0.001), in TI (r=−0.378, *p=0.039), and in T minor (r=−0.754, *p<0.001). The present finding implied a significantly higher ferritin and 
lower AMH in TM and TI that used DFO than DFP.
Conclusion: The results demonstrated that females with TM and TI were found to have lower serum AMH levels than T minor and inversely related 
to the serum ferritin levels in all thalassemic groups. Furthermore, it demonstrated that DFP was more efficient than DFO in removing excess iron 
and reducing the deleterious effect of excess iron to the reproductive system, which leads to fertility preservation of female patients with transfusion-
dependent β-thalassemia.
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INTRODUCTION
β-thalassemias are a group of hereditary blood disorders characterized 
by anomalies in the synthesis of the beta chains of hemoglobin resulting 
in variable phenotypes ranging from severe anemia to clinically 
asymptomatic individuals [1,2]. Thalassemia was first recognized as 
a disorder by researchers in the United States and Italy, in 1925 [3]. 
The name of the disease is derived from the Greek words, “thalassa” 
meaning sea and “haima” meaning blood due to the mistaken notion that 
the disease was restricted to individuals of Mediterranean origin [3]. 
β-thalassemia is prevalent in Mediterranean countries, the Middle East, 
Central Asia, India, Southern China, and the far East as well as countries 
along the North coast of Africa and in South America. 300,000-500,000 
children with a severe hemoglobin disorder are born each year, 30% of 
them have thalassemia. 50,000-100,000 children with beta-thalassemia 
major (TM) die each year in middle- and low-income countries [4]. In 
Egypt, β-thalassemia is the most common cause of chronic hemolytic 
anemia. The carrier rate varies between 5.5% and 9%. It was estimated 
that 1000/1.5 million/year live births have β-thalassemia [5].
β-thalassemia includes three main forms: TM, variably referred to as 
“cooley’s anemia” and “Mediterranean anemia,” thalassemia intermedia 
(TI) and thalassemia minor (T minor) also called “beta-thalassemia 
carrier”, “beta-thalassemia trait” or “heterozygous beta-thalassemia.” 
Individuals with TM usually present within the first 2 years of life 
with severe anemia, requiring regular red blood cell transfusions. 
Symptoms in untreated individuals with TM are growth retardation, 
pallor, jaundice, poor musculature, hepatosplenomegaly, leg ulcers, 
development of masses from extramedullary hematopoiesis, and 
skeletal changes that result from expansion of the bone marrow [6].
Treatment includes blood transfusions to correct anemia and iron 
chelating therapy to control iron overload [7-9]. Secondary iron 
overloading frequently results in target-organ toxicity such as heart 
failure, osteoporosis, or hypogonadism [10]. Two iron-chelating agents 
are approved to use: Subcutaneous deferoxamine (DFO) and synthetic 
oral deferiprone (DFP) [11]. The combination of the two iron chelators 
seems to maximize the efficacy producing additive and synergistic 
effects in iron excretion [12-14].
Advances in transfusions and iron chelation therapy have significantly 
improved the long-term survival and quality of life for women 
with transfusion-dependent β-thalassemia [15-18], evaluation of 
reproductive function in such women has become an emerging clinical 
issue [19,20]. Anti-müllerian hormone (AMH), also known as müllerian 
inhibiting substance, a member of the transforming growth factor-β 
superfamily, is primarily secreted by the granulosa cells of growing 
follicles [21]. Serum AMH levels have an excellent correlation with the 
number of antral follicles as determined by vaginal ultrasound [22,23].
Subjects
This study was conducted on 90 females that clinically diagnosed with 
β-thalassemia, 30 with TM, 30 with TI, and 30 with T minor. They were 
selected from hematology clinic-Cairo University (according to Scientific 
and Technological Cooperation Protocol between Faculty of Medicine, 
Cairo University, and Atomic Energy Authority, 2004). Written informed 
consent was obtained from all of the participants or their parents 
before blood sampling. The study was conducted in accordance with the 
guidelines set by the European Economic Community (EEC) regulations 
(Revised Directive 86/609/EEC) and approved by the Ethical 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Committee at National Center for Radiation Research, Egyptian Atomic 
Energy Authority, Cairo, Egypt (NCRR-EAEA). Their age ranged from 
10 to 25 years. The females with TM and TI received a blood transfusion 
every 3-4 weeks (transfusion characteristic and duration of transfusion 
were similar in all females). Females were prescribed DFO 40-50 mg/kg 
per infusion over 8-12 hrs, 5-6 days/week, or received DFP in regular 
oral dose (75 mg/kg/day when serum ferritin was <2500 ng/mL and 
100 mg/kg/day when serum ferritin was >2500 ng/mL).
For regularly transfused patients (TM and TI), blood samples were 
collected at least 2 weeks from the previous blood transfusion, and 
they were instructed to leave off from taking their chelator therapy 
for 24 hrs before blood sampling. Iron chelation therapy whether oral 
DFP (kelfer and ferriprox) or subcutaneous DFO (desferal), weight, 
height, and body mass index (BMI) of patients were recorded z-scores 
for weight, height, and BMI for females between 10 and 19 years were 
calculated using the World Health Organization reference data [24].
METHODS
Serum AMH was measured by enzyme-linked immunosorbent assay 
according to the manufacturer’s manual of a commercial kit purchased 
from EIAab Company, Catalog No: E0228h, China.
Serum ferritin was measured by immunoradiometric assay using a 
commercial kit purchased from Beckman Coulter, Immunotech, Czech 
Republic.
Statistical methods
The collected data were coded, tabulated, and statistically analyzed 
using IBM statistical package for social sciences statistics software 
version 22.0, IBM Corp, Chicago, USA, 2013. Mean, standard deviation, 
95% confidence interval, and minimum and maximum values were 
calculated for various parameters. Inferential analyses were performed 
for quantitative variables using independent T-test in cases of two 
independent groups, ANOVA test for more than two independent groups 
with post hoc Tukey test; homogenous groups, while correlations were 
done using Pearson correlations. The level of significance was taken at 
p<0.050 is significant, otherwise is nonsignificant.
RESULTS
A total of 90 patients were included in this study. Clinical history of 
study groups is summarized in Table 1. 30 patients had TM with a mean 
age (14.2 ± 3.7), 30 had TI with a mean age (13.3 ± 3.3), and 30 had T 
minor with a mean age (15.6 ± 3.9). There were no significant (0.242) 
differences between subjects with TM, TI, and T minor with respect 
to age as shown in Table 1. BMI z-score was significantly (<0.001) 
different among all studied groups; lowest in TM, followed by TI and 
highest in T minor. Ferritin was 25 fold more in TM than T minor 
(3088.0±2497.6 ng/ml vs. 120.3±36.2 ng/ml). Ferritin was significantly 
different among all studied groups as shown in Table 1. AMH (in all 
cases, prepubertal and postpubertal) was significantly highest in 
T minor, followed by TI and least in TM with no significant difference 
between TM and TI as shown in Table 1. There was a significant negative 
correlation between AMH and ferritin in TM (r=−0.949, *p<0.001) as 
shown in Fig. 1a, in TI (r=−0.378, *p=0.039) as shown in Fig. 1b, and 
in T minor (r=−0.754, *p<0.001) as shown in Fig. 1c. Patients with TM 
that used DFO (n=14) had lower AMH (0.4±0.2 ng/mL) and higher 
ferritin (4235.7±3238.9 ng/mL) than DFP (n=16) that had higher 
AMH (0.6±0.1 ng/mL), and lower ferritin (2083.8±814.3 ng/mL). Also, 
patients with TI that used DFO (n=10) had lower AMH (0.8±0.1 ng/mL) 
and higher ferritin (1405.0±846.7 ng/mL) than DFP (n=20) that had 
higher AMH (1.0±0.4 ng/mL), and lower ferritin (727.5±288.4 ng/mL).
DISCUSSION
Iron overload is one of the most important complications of regular blood 
transfusion. Excess iron is extremely toxic to all cells of the body and 
can cause serious and irreversible organic damage [25]. In thalassemia, 
effective management of iron overload requires monitoring both of iron 
toxicity and the effects of excessive chelation [26]. Serum ferritin is the 
most commonly employed test to evaluate iron overload in β-TM.
The present result revealed that ferritin was 25 fold more in TM than 
T minor (3088.0±2497.6 ng/mL vs. 120.3±36.2 ng/mL) and the data were 
significantly different among all studied groups. Despite our patients 
Fig. 1: (a-c) Correlations between ferritin and anti-müllerian 
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Table 1: Comparison between studied groups regarding history and clinical characteristics
Variables TM (n=30) TI (n=30) Minor (n=30) p
Family history 25 (83.3%)a 9 (30.0%)b 2 (6.7%)c 0.001*
Crisis 12 (40.0%)a 0 (0.0%)b 0 (0.0%)b 0.001*
Splenectomy 21 (70.0%)a 10 (33.3%)b 0 (0.0%)c 0.001*
Bony pain 30 (100.0%)a 25 (83.3%)b 0 (0.0%)c 0.001*
Fractures 6 (20.0%)a 0 (0.0%)b 0 (0.0%)b 0.002*
Dyspnea 30 (100.0%)a 3 (10.0%)b 0 (0.0%)b 0.001*
Palpitation 27 (90.0%)a 3 (10.0%)b 0 (0.0%)b 0.001*
Heart failure 2 (6.7%)a 0 (0.0%)a 0 (0.0%)a 0.129
Chelator
DFO 14 (46.7%)a 10 (33.3%)a - 0.292
DFP 16 (53.3%) 20 (66.7%) -
Transfusion age (months)
Mean±SD 5.6±1.5a 11.1±1.8b - 0.001*
Range 3.0-9.0 8.0-15.0 -
95% CI 5.0-6.1 10.5-11.8 -
Age (years)
Mean±SD 14.2±3.7a 13.3±3.3a 14.8±3.8a 0.242
Range 10.0-25.0 10.0-25.0 12.0-25.0
95% CI 12.8-15.6 12.1-14.5 13.4-16.3
BMI z -score
Mean±SD −0.93±1.08a −0.32±0.56b 0.85±0.87c 0.001*
Range −3.49-0.89 −1.72-0.76 −1.49-1.91
95% CI −1.35-0.50 −0.53-0.10 0.50-1.19
Ferritin (ng/mL)
Mean±SD 3088.0±2497.6a 1179.2±775.2b 120.3±36.2c 0.001*
Range 200.0-9500.0 350.0-3200.0 77.0-210.0
95% CI 2155.4-4020.6 889.7-1468.6 106.7-133.8
AMH (All) ng/mL
Mean±SD 0.5±0.2a 0.9±0.3a 2.0±1.1b 0.001*
Range 0.1-0.7 0.6-1.8 0.8-4.3
95% CI 0.4-0.6 0.8-1.0 1.6-2.4
AMH prepubertal ng/mL
Mean±SD 0.6±0.1a 0.9±0.3a 2.0±1.1b 0.001*
Range 0.2-0.7 0.6-1.8 0.9-4.3
95% CI 0.5-0.6 0.8-1.0 1.4-2.5
AMH postpubertal ng/mL
Mean±SD 0.4±0.2a 0.8±0.1a 2.1±1.1b 0.019*
Range 0.1-0.7 0.7-1.0 0.8-4.0
95% CI 0.2-0.5 0.7-1.0 1.4-2.7
*p<0.050, a,b,chomogenous groups had similar letters, TM: Thalassemia major, TI: Thalassemia intermedia, AMH: Anti-müllerian hormone, SD: Standard deviation, CI: 
Confidence interval, BMI: Body mass index, DFP: Deferiprone, DFO: Deferoxamine
regularly using iron-chelating agents, the mean ferritin level in TM was 
3088 ng/mL and in TI was 1179.2 ng/mL, which is above the desired 
level of 1000 ng/mL. Thus, the iron chelation could not be achieved as 
desired. These results agree with Pemde et al. [27] who stated that the 
mean ferritin level in patients with TM was 3138 ng/mL. Furthermore, 
Li et al. [28] stated that the mean ferritin level was 2729 ng/mL in 
11-19-year-old transfusion-dependent TM patients.
In our study, BMI z-score was significantly (p<0.001) different among all 
studied groups; lowest in TM, followed by TI and highest in T minor. Our 
findings were in agreement with the previous studies, Salih et al. [29] 
demonstrated that BMI of thalassemic patients is significantly lower 
than those in control group. Fahim et al. [30] reported that BMI was low 
in 43% of patients with β-TM than in controls. Furthermore, Hashemi 
et al. [31] reported low BMI in 18.6% of their patients with β-TM. 
Fig. 2: (a and b) Comparison between studied chelators among thalassemia major and thalassemia regarding ferritin and anti-müllerian 
hormone (AMH) levels respectively 
a b
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However other reports; claimed that the mean BMI of their thalassemic 
patients were in the normal range and insignificantly different than 
controls [32,33].
In thalassemia, long-term red blood cell transfusions in females may lead 
to iron deposition in the ovaries and further reduce the ovarian reserve. 
AMH concentration, unlike other ovarian hormones, has been reported 
to be constant throughout the menstrual cycle [34] and significantly 
decline with age [35]. Because of this consistency and reliability, serum 
AMH levels can be used as a marker of ovarian reserve [23]. Lee and 
co-worker [36] reported that AMH and chronological age were more 
accurate than basal follicle-stimulating hormone, antral follicle counts 
(AFC) and BMI to evaluate causes of infertility in the prediction of live 
birth rate. It has been documented that women with lower AMH and 
AFC produce a significantly lower number of oocytes compared with 
women with higher levels. AMH shows significant promise to serve as 
such a marker in thalassemia women with iron overload and seems a 
better marker than AFC [37]. The current results demonstrated that 
females with transfusion-dependent β-thalassemia were found to have 
lower serum AMH levels than T minor. There was a significantly negative 
correlation between AMH and ferritin in all studied groups. These 
results agree with Chang et al. [38] who stated low AMH concentration 
in women with transfusion-dependent β-thalassemia when compared 
with healthy women of a similar age, also noted that serum ferritin was 
significantly and inversely related to the AMH concentrations. While 
Singer et al. [37] demonstrated that levels of AMH were mostly normal.
The present finding implied a significantly higher ferritin and lower 
AMH in TM and TI that used DFO than DFP. The disadvantages of DFO 
are that it is not orally bioavailable, fast rate of metabolism necessitating 
prolonged parenteral infusions, poor compliance, chelates zinc 
(sometimes causing clinical zinc deficiency), and high cost [39].
Data of El-Beshlawy [40] who reported the Egyptian experience with 
the use of different oral iron chelators on thalassemia patients, showed 
unacceptable toxicity with the exception of DFP and ICL670. El-Beshlawy 
et al. [41] found that the toxicity of DFP was mild to moderate and 
acceptable. Recent and ongoing studies have demonstrated that DFP, a 
small molecule that permeates all tissues, is more efficient in removing 
cardiac iron and improving cardiac function than DFO [42,43].
CONCLUSION
In conclusion, the results demonstrated that females with TM and TI 
were found to have lower serum AMH levels than T minor and inversely 
related to the serum ferritin levels in all thalassemic females. The 
results of this study are consistent with the hypothesis that the ovarian 
reserve might be impaired in females with transfusion-dependent 
β-thalassemia because of iron overload. Furthermore, it demonstrated 
that DFP was more efficient than DFO in removing excess iron and 
reducing the deleterious effect of excess iron to the reproductive 
system, which leads to fertility preservation of female patients with 
transfusion-dependent β-thalassemia.
REFERENCES
1. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5:11.
2. Matin S, Jahromi MG, Karemizadeh Z, Haghpanah S, De Sanctis V, 
Soliman A, et al. The frequency of adrenal insufficiency in adolescents 
and young adults with thalassemia major versus thalassemia intermedia 
in Iran. Mediterr J Hematol Infect Dis 2015;7(1):e2015005.
3. Weatherall D. 2003 William Allan Award Address. The Thalassemias: 
The role of molecular genetics in an evolving global health problem. 
Am J Hum Genet 2004;74:385-92.
4. World Bank. Report of a Joint WHO-March of Dimes Meeting; 2006.
5. El-Beshlawy A, Kaddah N, Moustafa A, Mouktar G, Youssry I. 
Screening for beta-thalassaemia carriers in Egypt: Significance of the 
osmotic fragility test. East Mediterr Health J 2007;13:780-6.
6. Grow K, Vashist M, Abrol P, Sharma S, Yadav R. Beta thalassemia in 
India: Current status and the challenges ahead. Int J Pharm Pharm Sci 
2014;6(4):28-33.
7. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 
2005;353(11):1135-46.
8. Di Matteo R, Liuzza F, Pezzillo F, Gerardino L, Maccauro G. 
Subtrochanteric femoral fracture in a 26-year-old woman affected by 
β-talassemia major due to minor trauma: Analysis of bone modification 
causing the complication. Clin Ter 2007;158(5):425-9.
9. Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam 
Physician 2009;80(4):339-44.
10. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-
transfusion-dependent thalassemias. Haematologica 2013;98:833-44.
11. De Domenico I, Ward DM, Kaplan J. Specific iron chelators determine 
the route of ferritin degradation. Blood 2009;114:4546-51.
12. Grady RW, Berdoukas VA, Rachmielewitz EA. Optimizing chelation 
therapy: Combining deferiprone and desferrioxamine. 42nd Annual 
Meeting of the American Society of Hematology. San Francisco; 
2000.
13. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, et al. Combined 
therapy with deferiprone and desferrioxamine in thalassemia major. 
Haematologica 2005;90:1309-14.
14. Brittenham GM. Iron-chelating therapy for transfusional iron overload. 
N Engl J Med 2011;364(2):146-56.
15. Galanello R. A thalassemic child becomes adult. Rev Clin Exp Hematol 
2003;7(1):4-21.
16. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, 
et al. Survival of medically treated thalassemia patients in Cyprus. 
Trends and risk factors over the period 1980-2004. Haematologica 
2006;91:1187-92.
17. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. 
Improved survival of thalassaemia major in the UK and relation to 
T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 
2008;10:42.
18. Cunningham MJ. Update on thalassemia: Clinical care and 
complications. Pediatr Clin North Am 2008;55:447-60, ix.
19. Bajoria R, Chatterjee R. Current perspectives of fertility and pregnancy 
in thalassemia. Hemoglobin 2009;33 Suppl 1:S131-5.
20. Origa R, Piga A, Quarta G, Forni GL, Longo F, Melpignano A, et al. 
Pregnancy and beta-thalassemia: An Italian multicenter experience. 
Haematologica 2010;95:376-81.
21. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, 
Visser JA, et al. Anti-Müllerian hormone expression pattern in the 
human ovary: Potential implications for initial and cyclic follicle 
recruitment. Mol Hum Reprod 2004;10:77-83.
22. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, 
et al. Elevated serum level of anti-mullerian hormone in patients with 
polycystic ovary syndrome: Relationship to the ovarian follicle excess 
and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957-62.
23. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian 
hormone: A new marker for ovarian function. Reproduction 
2006;131(1):1-9.
24. WHO Growth Reference; 2007. Available from: http://www.who.int/
growthref/en/.
25. Melchiori L, Gardenghi S, Rivella S. Beta-thalassemia: HiJAKing 
ineffective erythropoiesis and iron overload. Adv Hematol 
2010;2010:938640.
26. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal 
outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol 
2002;15:329-68.
27. Pemde HK, Chandra J, Gupta D, Singh V, Sharma R, Dutta AK. 
Physical growth in children with transfusion-dependent thalassemia. 
Pediatr Health Med Ther 2011;2:13-9.
28. Li CK, Luk CW, Ling SC, Chik KW, Yuen HL, Li CK, et al. Morbidity 
and mortality patterns of thalassaemia major patients in Hong Kong: 
Retrospective study. Hong Kong Med J 2002;8:255-60.
29. Salih KM, Al-Mosawy WF. Evaluation some consequences of 
thalassemia major in splenectomized and non-splenectomized Iraqi 
patients. Int J Pharm Pharm Sci 2013;5 Suppl 4:385-8.
30. Fahim FM, Saad K, Askar EA, Eldin EN, Thabet AF. Growth parameters 
and vitamin D status in children with thalassemia major in upper Egypt. 
Int J Hematol Oncol Stem Cell Res 2013;7:10-4.
31. Hashemi A, Ghilian R, Golestan M, Akhavan GM, Zare Z, 
Dehghani MA. The study of growth in thalassemic patients and its 
correlation with serum ferritin level. Iran J Pediatr Hematol Oncol 
2011;1(4):147-51.
32. Vogiatzi MG, Macklin EA, Trachtenberg FL, Fung EB, Cheung AM, 
Vichinsky E, et al. Differences in the prevalence of growth, endocrine 
and vitamin D abnormalities among the various thalassaemia syndromes 
in North America. Br J Haematol 2009;146:546-56.
33. Hamed EA, ElMelegy NT. Renal functions in pediatric patients 
267
Asian J Pharm Clin Res, Vol 10, Issue 4, 2017, 263-267
 El-Desouky et al. 
with beta-thalassemia major: Relation to chelation therapy: Original 
prospective study. Ital J Pediatr 2010;36:39.
34. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, 
Broekmans FJ. Anti-müllerian hormone levels in the spontaneous 
menstrual cycle do not show substantial fluctuation. J Clin Endocrinol 
Metab 2006;91:4057-63.
35. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimüllerian 
hormone serum levels: A putative marker for ovarian aging. Fertil Steril 
2002;77(2):357-62.
36. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS. Impact of 
female age and male infertility on ovarian reserve markers to predict 
outcome of assisted reproduction technology cycles. Reprod Biol 
Endocrinol 2009;7:100.
37. Singer ST, Vichinsky EP, Gildengorin G, van Disseldorp J, Rosen M, 
Cedars MI. Reproductive capacity in iron overloaded women with 
thalassemia major. Blood 2011;118(10):2878-81.
38. Chang HH, Chen MJ, Lu MY, Chern JP, Lu CY, Yang YL, et al. Iron 
overload is associated with low anti-müllerian hormone in women with 
transfusion-dependent ß-thalassaemia. BJOG 2011;118:825-31.
39. Prabhu R, Prabhu V, Prabhu RS. Iron overload in beta thalassemia - A 
review. J Bio Sci Technol 2009;1(1):20-31.
40. El Beshlawy A. The Egyptian experience with oral iron chelators. 
Hematology 2005;10 Suppl 1:174-5.
41. El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, 
et al. Iron chelation in thalassemia: Combined or monotherapy? The 
Egyptian experience. Ann Hematol 2008;87(7):545-50.
42. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety 
monitoring of cardiac and hepatic systems in beta-thalassemia 
patients with chelating treatment in Taiwan. Eur J Haematol 
2003;70:392-7.
43. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, 
et al. Randomized controlled trial of deferiprone or deferoxamine 
in beta-thalassemia major patients with asymptomatic myocardial 
siderosis. Blood 2006;107(9):3738-44.
